|
|
|
|
|
|
最高研发阶段临床3期 |
首次获批国家/地区- |
首次获批日期- |
|
|
|
|
|
非在研适应症- |
最高研发阶段临床1期 |
首次获批国家/地区- |
首次获批日期- |
A dose finding study with an active control group (Yasmin) to assess the contraceptive efficacy and the efficacy on liver function of estetrol combined with 3 mg drospirenone by daily oral administration to healthy female volunteers for 3 cycles of 24 days each followed by a 4 day treatment pause. - DOC-2
Double-blind, placebo-controlled, randomised N=1 study to determine the effect of concomitant treatment with dehydroepiandrosterone on mood in women who experience mood disturbances during oral contraception-use
A double-blind, placebo-controlled, randomised, N=1 study to determine the effect of concomitant treatment with dehydroepiandrosterone (50 mg) on mood in women who experience mood disturbances during oral contraception-use. - ARC-MOOD
100 项与 Pantarhei Bioscience BV 相关的临床结果
0 项与 Pantarhei Bioscience BV 相关的专利(医药)
100 项与 Pantarhei Bioscience BV 相关的药物交易
100 项与 Pantarhei Bioscience BV 相关的转化医学